Hypertension delays viral clearance and exacerbates airway hyperinflammation in patients with COVID-19
In coronavirus disease 2019 (COVID-19), hypertension and cardiovascular diseases are major risk factors for critical disease progression. However, the underlying causes and the effects of the main anti-hypertensive therapies-angiotensin-converting enzyme inhibitors (ACEIs) and angiotensin receptor blockers (ARBs)-remain unclear. Combining clinical data (n = 144) and single-cell sequencing data of airway samples (n = 48) with in vitro experiments, we observed a distinct inflammatory predisposition of immune cells in patients with hypertension that correlated with critical COVID-19 progression. ACEI treatment was associated with dampened COVID-19-related hyperinflammation and with increased cell intrinsic antiviral responses, whereas ARB treatment related to enhanced epithelial-immune cell interactions. Macrophages and neutrophils of patients with hypertension, in particular under ARB treatment, exhibited higher expression of the pro-inflammatory cytokines CCL3 and CCL4 and the chemokine receptor CCR1. Although the limited size of our cohort does not allow us to establish clinical efficacy, our data suggest that the clinical benefits of ACEI treatment in patients with COVID-19 who have hypertension warrant further investigation.
| Errataetall: |
CommentIn: Nat Rev Cardiol. 2021 Apr;18(4):231. - PMID 33462417 |
|---|---|
| Medienart: |
E-Artikel |
| Erscheinungsjahr: |
2021 |
|---|---|
| Erschienen: |
2021 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:39 |
|---|---|
| Enthalten in: |
Nature biotechnology - 39(2021), 6 vom: 24. Juni, Seite 705-716 |
| Sprache: |
Englisch |
|---|
| Links: |
|---|
| Anmerkungen: |
Date Completed 22.06.2021 Date Revised 28.01.2023 published: Print-Electronic CommentIn: Nat Rev Cardiol. 2021 Apr;18(4):231. - PMID 33462417 Citation Status MEDLINE |
|---|
| doi: |
10.1038/s41587-020-00796-1 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM319261301 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM319261301 | ||
| 003 | DE-627 | ||
| 005 | 20231225171059.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231225s2021 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1038/s41587-020-00796-1 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1064.xml |
| 035 | |a (DE-627)NLM319261301 | ||
| 035 | |a (NLM)33361824 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Trump, Saskia |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Hypertension delays viral clearance and exacerbates airway hyperinflammation in patients with COVID-19 |
| 264 | 1 | |c 2021 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 22.06.2021 | ||
| 500 | |a Date Revised 28.01.2023 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a CommentIn: Nat Rev Cardiol. 2021 Apr;18(4):231. - PMID 33462417 | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a In coronavirus disease 2019 (COVID-19), hypertension and cardiovascular diseases are major risk factors for critical disease progression. However, the underlying causes and the effects of the main anti-hypertensive therapies-angiotensin-converting enzyme inhibitors (ACEIs) and angiotensin receptor blockers (ARBs)-remain unclear. Combining clinical data (n = 144) and single-cell sequencing data of airway samples (n = 48) with in vitro experiments, we observed a distinct inflammatory predisposition of immune cells in patients with hypertension that correlated with critical COVID-19 progression. ACEI treatment was associated with dampened COVID-19-related hyperinflammation and with increased cell intrinsic antiviral responses, whereas ARB treatment related to enhanced epithelial-immune cell interactions. Macrophages and neutrophils of patients with hypertension, in particular under ARB treatment, exhibited higher expression of the pro-inflammatory cytokines CCL3 and CCL4 and the chemokine receptor CCR1. Although the limited size of our cohort does not allow us to establish clinical efficacy, our data suggest that the clinical benefits of ACEI treatment in patients with COVID-19 who have hypertension warrant further investigation | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Research Support, Non-U.S. Gov't | |
| 650 | 7 | |a Angiotensin Receptor Antagonists |2 NLM | |
| 650 | 7 | |a Angiotensin-Converting Enzyme Inhibitors |2 NLM | |
| 650 | 7 | |a CCL3 protein, human |2 NLM | |
| 650 | 7 | |a CCL4 protein, human |2 NLM | |
| 650 | 7 | |a CCR1 protein, human |2 NLM | |
| 650 | 7 | |a Chemokine CCL3 |2 NLM | |
| 650 | 7 | |a Chemokine CCL4 |2 NLM | |
| 650 | 7 | |a Receptors, CCR1 |2 NLM | |
| 700 | 1 | |a Lukassen, Soeren |e verfasserin |4 aut | |
| 700 | 1 | |a Anker, Markus S |e verfasserin |4 aut | |
| 700 | 1 | |a Chua, Robert Lorenz |e verfasserin |4 aut | |
| 700 | 1 | |a Liebig, Johannes |e verfasserin |4 aut | |
| 700 | 1 | |a Thürmann, Loreen |e verfasserin |4 aut | |
| 700 | 1 | |a Corman, Victor Max |e verfasserin |4 aut | |
| 700 | 1 | |a Binder, Marco |e verfasserin |4 aut | |
| 700 | 1 | |a Loske, Jennifer |e verfasserin |4 aut | |
| 700 | 1 | |a Klasa, Christina |e verfasserin |4 aut | |
| 700 | 1 | |a Krieger, Teresa |e verfasserin |4 aut | |
| 700 | 1 | |a Hennig, Bianca P |e verfasserin |4 aut | |
| 700 | 1 | |a Messingschlager, Marey |e verfasserin |4 aut | |
| 700 | 1 | |a Pott, Fabian |e verfasserin |4 aut | |
| 700 | 1 | |a Kazmierski, Julia |e verfasserin |4 aut | |
| 700 | 1 | |a Twardziok, Sven |e verfasserin |4 aut | |
| 700 | 1 | |a Albrecht, Jan Philipp |e verfasserin |4 aut | |
| 700 | 1 | |a Eils, Jürgen |e verfasserin |4 aut | |
| 700 | 1 | |a Hadzibegovic, Sara |e verfasserin |4 aut | |
| 700 | 1 | |a Lena, Alessia |e verfasserin |4 aut | |
| 700 | 1 | |a Heidecker, Bettina |e verfasserin |4 aut | |
| 700 | 1 | |a Bürgel, Thore |e verfasserin |4 aut | |
| 700 | 1 | |a Steinfeldt, Jakob |e verfasserin |4 aut | |
| 700 | 1 | |a Goffinet, Christine |e verfasserin |4 aut | |
| 700 | 1 | |a Kurth, Florian |e verfasserin |4 aut | |
| 700 | 1 | |a Witzenrath, Martin |e verfasserin |4 aut | |
| 700 | 1 | |a Völker, Maria Theresa |e verfasserin |4 aut | |
| 700 | 1 | |a Müller, Sarah Dorothea |e verfasserin |4 aut | |
| 700 | 1 | |a Liebert, Uwe Gerd |e verfasserin |4 aut | |
| 700 | 1 | |a Ishaque, Naveed |e verfasserin |4 aut | |
| 700 | 1 | |a Kaderali, Lars |e verfasserin |4 aut | |
| 700 | 1 | |a Sander, Leif-Erik |e verfasserin |4 aut | |
| 700 | 1 | |a Drosten, Christian |e verfasserin |4 aut | |
| 700 | 1 | |a Laudi, Sven |e verfasserin |4 aut | |
| 700 | 1 | |a Eils, Roland |e verfasserin |4 aut | |
| 700 | 1 | |a Conrad, Christian |e verfasserin |4 aut | |
| 700 | 1 | |a Landmesser, Ulf |e verfasserin |4 aut | |
| 700 | 1 | |a Lehmann, Irina |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Nature biotechnology |d 1996 |g 39(2021), 6 vom: 24. Juni, Seite 705-716 |w (DE-627)NLM08998398X |x 1546-1696 |7 nnns |
| 773 | 1 | 8 | |g volume:39 |g year:2021 |g number:6 |g day:24 |g month:06 |g pages:705-716 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1038/s41587-020-00796-1 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 39 |j 2021 |e 6 |b 24 |c 06 |h 705-716 | ||